COMPANY PROFILE

Apic Bio

Explore full profile

Advancing therapies to treat rare diseases

Cambridge, United StatesFounded 2017Biotech & Life Sciences

Valuation $100–250M Last recorded · 2019

Headcount <100 Current team size

Total funding $50–100M Disclosed equity funding

Unlock exact values

About Apic Bio

Apic Bio, Inc. is a pioneering gene therapy company focused on developing novel treatment options for patients suffering from rare, monogenic disorders that have limited or no approved treatments. Operating in the biotechnology sector, Apic Bio serves patients and healthcare providers by leveraging its proprietary dual function silence and replace platform. This technology uses a single vector to simultaneously silence and replace damaged genes, offering a unique approach to gene therapy. The company primarily targets genetic conditions such as SOD1 ALS, for which it has received Orphan Drug Designation from the FDA. Apic Bio's business model revolves around research and development, clinical trials, and eventual commercialization of its gene therapy solutions. Revenue is generated through partnerships, grants, and potential future sales of approved therapies.

MoreLess Source: Dealroom company data

At a glance

Status: Operational
Founded: 2017
Headquarters: Cambridge, United States
Employees: 6
Open positions: None listed
Dealroom signal: 56.0/100
Industry: Health
Sub-industry: BioTechnology
Sector: Biotech & Life Sciences, Biotechnology, Spinout, Biotech and Pharma, DT and LS, science-based
Client focus: b2b
Investment activity: 1 company, latest Jan 2019
Capital deployed: $59M
Preferred round: SERIES A
Links: Website X

Knowledge graph

Founder mafia, market maps, research and news connected to this company by Dealroom

Funding history

5 recorded events

Company financing events and reported valuations.

Deal type	Date	Amount	Valuation	Investors	Source
DEBTDebt	May 2021	$4.7M	—	Undisclosed	—
SERIES AOther financing	Jan 2019	$40M	$160M	Morningside · ALS Investment Fund	↗

Showing the latest 2 of 5 recorded eventsBook a demo for the full funding history →

Growth signals

Apic Bio website traffic

Latest recorded traffic for Apic Bio is 160 monthly website visits, down 71.9% over the last three months. Apic Bio's team grew 0% over the past year.

Latest monthly visits160 3-month web change-71.9% 1-year team growth0%

Monthly website visitsOct 2017–May 2024

Explore monthly traffic historyTrack growth over time and compare with peersBook a demo

Summary metrics are public; monthly history is available with a demoCompare with peers →

Similar companies

Closest operating peers by Dealroom taxonomy

Company identity and context are open; selected comparison metrics preview what is available on the platform.

Company	Headquarters	Status	Employees	Total funding	Valuation
XBxCystence BioTherapeutics for Polycystic Kidney Disease treatment	District of Tuggeranong, Australia	Operational	3	$485K	—
AVAviadoBioPrecision gene therapies for neurodegenerative disorders	London, United Kingdom	Operational
TTTay TherapeuticsBiotech platform enhancing patient-specific medicines through advanced discovery and development expertise	Dundee, United Kingdom	Operational
AIAiberRemote medical support technology for aviation and maritime	Winshill, United Kingdom	Operational
EHEdifice HealthOffers inflammatory health monitoring tests to help manage chronic inflammation and improve overall health and longevity	San Mateo, United States	Operational
NENeomorphDeveloping novel drugs targeting previously untreatable disease-causing proteins using molecular degradation technology	San Diego, United States	Operational
CTCV6 TherapeuticsCombination therapies enhancing cornerstone cancer and inflammatory treatments	Belfast, United Kingdom	Operational
GEGelmetixInjectable polymer gel for non-surgical chronic pain treatment	London, United Kingdom	Operational